TD Cowen analyst Ritu Baral raised the firm’s price target on Insmed (INSM) to $231 from $223 and keeps a Buy rating on the shares. The firm said Brinsupri, the company’s 1st-gen neutrophil elastase inhibitor, received formal EC approval for NCFBE ‘with 2+ exacerbations’ in the prior year. Insmed will secure access starting early 2026, likely with an initial German launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Brinsupri Approval and Strategic Market Expansion Justify Buy Rating
- Insmed’s BRINSUPRI Approved by European Commission
- Insmed’s Brinsupri approved in EU for non-cystic fibrosis bronchiectasis
- Insmed price target raised to $225 from $196 at Goldman Sachs
- Insmed price target raised to $214 from $139 at Truist